期刊文献+

胰腺癌的综合治疗

原文传递
导出
摘要 全球每年约有15万人,欧洲约有4万人死于胰腺癌,胰腺癌的发病率在全球范围内呈上升趋势。尽管影像学诊断技术和外科手术技术在不断提高.但其术后生存率并没有突破性改变。早期胰腺癌手术切除率为90%~100%,5年生存率可达70%~100%,但胰腺癌具有早期浸润血管,早期“围胆管”侵犯,早期神经束侵犯及早期缺乏特征性症状与体征的生物学特性,致使近90%的患者就诊时已属晚期,手术切除率仅为10%,5年生存率不足4%。
作者 王宏磊 江涛
出处 《中华胰腺病杂志》 CAS 2010年第3期215-217,共3页 Chinese Journal of Pancreatology
  • 相关文献

参考文献2

二级参考文献24

  • 1HERBST RS,BAJORIN DF,BLEIBERG H,et al.Clinical cancer advances 2005:major research advances in cancer treatment,prevention and screaning-a report from the Aamerican Society of Clinical Oncology[J].J Clin Oncol,2006,24 (1):190-205.
  • 2NYGREN P,SORBYE H,OSTERLUND P,et al.Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab:an acta oncologica expert report[J].Acta Oncol,2005; 44 (3):203-217.
  • 3MARTY M,COGNETTI F,MARANINCHI D.et al.Randomized phase Ⅱ trial fo the efficacy and satety of trastuzumab combined with docetoxel in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274.
  • 4TAKANO T,OHE Y,SAKAMOTO H,et al.Epidermal growth factor receptor genemutations and increased copy numbers predict Gifitinib sensitivity in patients with recurrent non small cell lung cancer[J].J Clin Oncol,2005,23 (28):6829-6837.
  • 5SALTZ LB,MEROPOL NJ,LOEHRER PJ,etal.Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(7):1201-1208.
  • 6REYNOLDS NA,WAGSTAFF AJ.Cetuximab:in the treatment of metastatic colorectal cancer[J].Drugs,2004,64 (1):109-121.
  • 7SPARANO J A,GRAY R,G1IANTONIO B,et al.Evaluating antiangiogenesis agents in the clinic:the Eastern Cooperative Oncology Group Portfolio of Clinical Trials[J].Clin Cancer Res,2004,10(4):1206-1211.
  • 8HURWITZ HI,FEHRENBACHER L,HAINSWORTH JD,et al.Bevacizumab in combination with fluorouracil and leucovorin:an active regimen for first-line metastatic colorectal cancer[J].J Clin Oncol,2005,23(15):3502-3508.
  • 9LYNCH TJ,BELL DW,SORDELLA R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
  • 10SMITH J K,MAMOON N M,DUHE RJ.Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy[J].Oncol Res,2004,14(4-5):175-225.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部